ATBPF News and Press, Antibe Therapeutics From 08/03/21

- Current AME study paused in adherence to safety protocol Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absorption, metabolism ...

Antibe Therapeutics, Inc. (ATBPF): FY GAAP EPS of -C$0.70.Revenue of C$9.7M (-2.8% Y/Y)Press Release For further details see: Antibe Therapeutics, Inc. reports FY results

- Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week - Ended year with a strong $72 million cash position, providing over two years of runway and fully funding Phase III adaptive trial Antibe Therapeutics Inc. (TSX: AT...

Antibe Therapeutics (ATBPF) announces a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and bolster the company's intellectual property (“IP”) position for its current pipeline.Dalriada is a contract research organization (“CRO”)...

- Enables rapid advancement of multiple drug discovery programs to exploit hydrogen sulfide platform in new disease areas Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation sa...

Antibe Therapeutics (OTCQX: ATBPF) is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company's current pipeline includes three assets that seek to overcome the gastro...

- Amalgamation secures 100% ownership of IP underlying Antibe’s pipeline - Strengthens position in large-market partnering discussions Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (“Antibe” or the “Company”), a clinical stage c...

The following slide deck was published by Antibe Therapeutics, Inc. in conjunction with this event. For further details see: Antibe Therapeutics (ATBPF) Investor Presentation - Slideshow

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, is pleased to announce its participation in the Bloom Burton ...

- Enables expansion to U.S.-based clinical trials, advances preparation for Phase III program Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation ...